Should I buy or sell Galera Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" GRTX shares. View GRTX analyst ratings or view top-rated stocks .

How have GRTX shares performed in 2024?

Galera Therapeutics' stock was trading at $0.1454 at the beginning of the year. Since then, GRTX shares have increased by 16.9% and is now trading at $0.1699. View the best growth stocks for 2024 here .

Are investors shorting Galera Therapeutics?

Galera Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 1,770,000 shares, a decrease of 36.8% from the March 15th total of 2,800,000 shares. Based on an average trading volume of 2,380,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 4.1% of the company's stock are sold short. View Galera Therapeutics' Short Interest .

When is Galera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GRTX earnings forecast .

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics, Inc. (NASDAQ:GRTX) released its earnings results on Wednesday, November, 10th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.15.

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC) , Ardelyx (ARDX) , Chiasma (CHMA) , Provention Bio (PRVB) , Seelos Therapeutics (SEEL) , Soligenix (SNGX) , TG Therapeutics (TGTX) and VBI Vaccines (VBIV) .

When did Galera Therapeutics IPO?

Galera Therapeutics (GRTX) raised $75 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Galera Therapeutics?

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GRTX

Galera Therapeutics (GRTX) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free GRTX Stock Alerts

$0.17

+0.02 (+11.12%)

(As of 01:21 PM ET)

Compare

Today's Range: $0.15
▼
$0.17
50-Day Range: $0.14
▼
$0.27
52-Week Range: $0.09
▼
$3.59

Volume: 757,904 shs
Average Volume: 2.18 million shs
Market Capitalization: $9.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Galera Therapeutics alerts:

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Galera Therapeutics Stock (NASDAQ:GRTX)

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

GRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GRTX Stock News Headlines

April 16, 2024 | americanbankingnews.com

Galera Therapeutics (NASDAQ:GRTX) Trading Down 3.8%

April 1, 2024 | msn.com

Galera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory Challenges

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 28, 2024 | finanznachrichten.de

Galera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

March 28, 2024 | globenewswire.com

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

March 16, 2024 | finance.yahoo.com

GRTX Apr 2024 0.500 call

March 12, 2024 | nz.finance.yahoo.com

Galera Therapeutics, Inc. (GRTX)

February 27, 2024 | edition.cnn.com

Galera Therapeutics, Inc.

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

February 4, 2024 | investing.com

Galera Therapeutics Inc (GRTX)

February 4, 2024 | benzinga.com

Galera Therapeutics Stock (NASDAQ:GRTX) Dividends: History, Yield and Dates

January 21, 2024 | finance.yahoo.com

Galera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17

January 16, 2024 | bizjournals.com

Local publicly traded stocks lag far behind national indices in 2023

January 9, 2024 | msn.com

Dow Tumbles Over 200 Points; US Trade Gap Narrows In November

November 28, 2023 | msn.com

Galera Therapeutics (GRTX) Price Target Increased by 7.14% to 0.38

November 14, 2023 | finanznachrichten.de

Galera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

November 14, 2023 | benzinga.com

Galera Therapeutics: Q3 Earnings Insights

November 14, 2023 | finance.yahoo.com

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

November 13, 2023 | benzinga.com

Galera Therapeutics's Earnings Outlook

November 1, 2023 | benzinga.com

US Stocks Fall; Pfizer Swings To Q3 Loss

October 31, 2023 | benzinga.com

Dow Gains 50 Points; Global Payments Posts Upbeat Earnings

October 31, 2023 | bizjournals.com

Galera Therapeutics warns of potential shutdown as it halts clinical trials and stock tanks

October 31, 2023 | msn.com

Why Is Cancer Focused Galera Therapeutics Stock Sinking Today?

October 31, 2023 | msn.com

Galera plunges after citing risks to business continuity

October 31, 2023 | finanznachrichten.de

Galera Therapeutics: Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

October 31, 2023 | finance.yahoo.com

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

September 19, 2023 | markets.businessinsider.com

Galera Therapeutics (GRTX) Gets a Hold from H.C. Wainwright

See More Headlines

Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GRTX
CUSIP: N/A
CIK: 1563577
Web: www.galeratx.com
Phone: 610-725-1500
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -137.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.36
Quick Ratio: 4.36

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.41) per share
Price / Book: -0.07

Miscellaneous

Outstanding Shares: 54,390,000
Free Float: 50,639,000
Market Cap: $9.24 million
Optionable: Optionable
Beta: 2.17

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. J. Mel Sorensen M.D. (Age 67)
CEO, President & Director
Comp: $908.35k
Mr. Christopher Degnan (Age 44)
Chief Financial Officer
Comp: $603.52k
Dr. Robert A. Beardsley M.B.A. (Age 63)
Ph.D., Co-Founder & COO
Comp: $627.52k
Ms. Jennifer Evans Stacey Esq. (Age 59)
Chief Legal & Compliance Officer and Secretary
Ms. Andie Collier
Chief Regulatory & Quality Affairs Officer
Ms. Judy Schnyder
Senior Vice President of Clinical Operations & Data Management

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Galera Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" GRTX shares.
View GRTX analyst ratings or view top-rated stocks.
How have GRTX shares performed in 2024?: Galera Therapeutics' stock was trading at $0.1454 at the beginning of the year. Since then, GRTX shares have increased by 16.9% and is now trading at $0.1699.
View the best growth stocks for 2024 here.
Are investors shorting Galera Therapeutics?: Galera Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 1,770,000 shares, a decrease of 36.8% from the March 15th total of 2,800,000 shares. Based on an average trading volume of 2,380,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 4.1% of the company's stock are sold short.
View Galera Therapeutics' Short Interest.
When is Galera Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GRTX earnings forecast.

How were Galera Therapeutics' earnings last quarter?: Galera Therapeutics, Inc. (NASDAQ:GRTX) released its earnings results on Wednesday, November, 10th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.15.
What other stocks do shareholders of Galera Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV).
When did Galera Therapeutics IPO?: Galera Therapeutics (GRTX) raised $75 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Galera Therapeutics?: Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Galera Therapeutics (GRTX) Stock Price, News & Analysis

About Galera Therapeutics Stock (NASDAQ:GRTX)

GRTX Stock Price History

GRTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

GRTX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info